【摘要】 目的 分析LADA患者的临床特征, 以提高其防治水平。 方法 选取临床新诊断的LADA患者51例，同时选择50例新诊断T2DM患者作为对照组。所有研究对象均测量身高、体重、WHR、BP，并测定FPG、血脂、C-P、Ins、HbA1c，标准餐后2hPG、C-P。比较两组患者的胰岛素分泌指数(HOMA-β)和胰岛素抵抗指数(HOMA -IR)。 结果 LADA发病年龄范围较广，部分LADA患者体形肥胖，伴有高血压和(或)血脂异常。LADA组的HOMA-β低于T2DM组(P<0.05)，两组间HOMA–IR比较差异无统计学意义(P>0.05)。结论 LADA患者临床表现具有很大的异质性。患者体内既存在胰岛素缺乏，又有胰岛素抵抗。胰岛自身抗体检测有助诊断，诊断后需要尽早使用胰岛素治疗，可配合应用胰岛素增敏剂治疗。

　　【关键词】 成人隐匿性自身免疫糖尿病;胰岛素自身抗体;胰岛素抵抗;胰岛素增敏剂

　　Analysis on the clinical features with latent autoimmune diabetes in adults SUN Sheng-hua1, SONG Qin-hua1, LIU Hai-wei2, et al. 1. Department of Endocrinology, The Affiliated Hospital of Hainan Medical College; 2. Department of Endocrinology, Hainan Provincial People’s Hospital, Haikou 570102, China

　　Corresponding author: SUN Sheng-hua, E-mail: ssh1234@163.com

　　【Abstract】 Objective To analyze the clinical characteristics of the latent autoimmune diabetes in adults (LADA) to improve the prevention of this disease. Methods Fifty-one newly diagnosed LADA patients were enrolled and fifty newly diagnosed T2DM patients served as the control. The levels of HOMA-βand HOMA-IR in two groups were analyzed through the comparison of the height, weight, waist-hip ratio (WHR), blood pressure (BP), fasting plasma glucose (FPG), blood lipid, C-peptide, insulin， HbA1c, and standard 2-hour postprandial plasma glucose (2hPG) and fasting C-peptide (FC-P) in all subjects. Results Among the LADA patients there was a wide range of age，and some of them were obese with high blood pressure and/or lipid abnormalities. HOMA-βin the LADA group was lower than that in the T2DM group (P<0.05)，and the difference of HOMA-IR between the two groups was not significant (P>0.05). Conclusions Clinical manifestations in LADA patients are significantly heterogenetic. The patients have both insulin deficiency and insulin resistance. The islet autoantibody test is helpful in diagnosis of LADA. Early application of insulin is needed and insulin sensitizer can be accompanied for their treatment.

　　【Key words】 Latent autoimmune diabetes in adults (LADA); Insulin autoantibody; Insulin resistance; Insulin sensitizer